<?xml version='1.0' encoding='utf-8'?>
<document id="30851617"><sentence text="Assessment of preclinical drug interactions of bedaquiline by a highly sensitive LC-ESI-MS/MS based bioanalytical method."><entity charOffset="47-58" id="DDI-PubMed.30851617.s1.e0" text="bedaquiline" /></sentence><sentence text="A continuous effort has been given to find out a new drug that is effective against tuberculosis (TB) from both susceptible and resistant strains of Mycobacterium tuberculosis" /><sentence text=" Bedaquiline represents a recently approved anti-TB drug, which has a unique mechanism of action to fight against multi drug resistance (MDR)"><entity charOffset="1-12" id="DDI-PubMed.30851617.s3.e0" text="Bedaquiline" /></sentence><sentence text=" Some severe side effects and drug-drug interactions are associated with the treatment of bedaquiline"><entity charOffset="90-101" id="DDI-PubMed.30851617.s4.e0" text="bedaquiline" /></sentence><sentence text=" Moreover, World Health Organisation (WHO) has also been provided guidelines in the year of 2013 for the use of bedaquiline and encourages additional investigation into it"><entity charOffset="112-123" id="DDI-PubMed.30851617.s5.e0" text="bedaquiline" /></sentence><sentence text=" Hence, the pharmacokinetics of bedaquiline upon coadministration with the drug has to be explored in the preclinical model and for which a liquid chromatography tandem mass spectrometry (LC-MS/MS) based bioanalytical method for quantitation of bedaquiline will be useful"><entity charOffset="32-43" id="DDI-PubMed.30851617.s6.e0" text="bedaquiline" /><entity charOffset="245-256" id="DDI-PubMed.30851617.s6.e1" text="bedaquiline" /><pair ddi="false" e1="DDI-PubMed.30851617.s6.e0" e2="DDI-PubMed.30851617.s6.e0" /><pair ddi="false" e1="DDI-PubMed.30851617.s6.e0" e2="DDI-PubMed.30851617.s6.e1" /></sentence><sentence text=" A simple, sensitive and rapid LC-MS/MS method was developed, validated and successfully applied to drug interactions of bedaquiline upon coadministration with cytochrome P450 3A4 (CYP3A4) inducers/inhibitors orally in Wistar rats"><entity charOffset="121-132" id="DDI-PubMed.30851617.s7.e0" text="bedaquiline" /></sentence><sentence text=" Results reveal that ciprofloxacin and fluconazole have marked effect to hinder the pharmacokinetics of bedaquiline but isoniazid, verapamil and carbamazepine have no significant effect on bedaquiline pharmacokinetics"><entity charOffset="21-34" id="DDI-PubMed.30851617.s8.e0" text="ciprofloxacin" /><entity charOffset="39-50" id="DDI-PubMed.30851617.s8.e1" text="fluconazole" /><entity charOffset="104-115" id="DDI-PubMed.30851617.s8.e2" text="bedaquiline" /><entity charOffset="120-129" id="DDI-PubMed.30851617.s8.e3" text="isoniazid" /><entity charOffset="131-140" id="DDI-PubMed.30851617.s8.e4" text="verapamil" /><entity charOffset="145-158" id="DDI-PubMed.30851617.s8.e5" text="carbamazepine" /><entity charOffset="189-200" id="DDI-PubMed.30851617.s8.e6" text="bedaquiline" /><pair ddi="false" e1="DDI-PubMed.30851617.s8.e0" e2="DDI-PubMed.30851617.s8.e0" /><pair ddi="false" e1="DDI-PubMed.30851617.s8.e0" e2="DDI-PubMed.30851617.s8.e1" /><pair ddi="false" e1="DDI-PubMed.30851617.s8.e0" e2="DDI-PubMed.30851617.s8.e2" /><pair ddi="false" e1="DDI-PubMed.30851617.s8.e0" e2="DDI-PubMed.30851617.s8.e3" /><pair ddi="false" e1="DDI-PubMed.30851617.s8.e0" e2="DDI-PubMed.30851617.s8.e4" /><pair ddi="false" e1="DDI-PubMed.30851617.s8.e0" e2="DDI-PubMed.30851617.s8.e5" /><pair ddi="false" e1="DDI-PubMed.30851617.s8.e0" e2="DDI-PubMed.30851617.s8.e6" /><pair ddi="false" e1="DDI-PubMed.30851617.s8.e1" e2="DDI-PubMed.30851617.s8.e1" /><pair ddi="false" e1="DDI-PubMed.30851617.s8.e1" e2="DDI-PubMed.30851617.s8.e2" /><pair ddi="false" e1="DDI-PubMed.30851617.s8.e1" e2="DDI-PubMed.30851617.s8.e3" /><pair ddi="false" e1="DDI-PubMed.30851617.s8.e1" e2="DDI-PubMed.30851617.s8.e4" /><pair ddi="false" e1="DDI-PubMed.30851617.s8.e1" e2="DDI-PubMed.30851617.s8.e5" /><pair ddi="false" e1="DDI-PubMed.30851617.s8.e1" e2="DDI-PubMed.30851617.s8.e6" /><pair ddi="false" e1="DDI-PubMed.30851617.s8.e2" e2="DDI-PubMed.30851617.s8.e2" /><pair ddi="false" e1="DDI-PubMed.30851617.s8.e2" e2="DDI-PubMed.30851617.s8.e3" /><pair ddi="false" e1="DDI-PubMed.30851617.s8.e2" e2="DDI-PubMed.30851617.s8.e4" /><pair ddi="false" e1="DDI-PubMed.30851617.s8.e2" e2="DDI-PubMed.30851617.s8.e5" /><pair ddi="false" e1="DDI-PubMed.30851617.s8.e2" e2="DDI-PubMed.30851617.s8.e6" /><pair ddi="false" e1="DDI-PubMed.30851617.s8.e3" e2="DDI-PubMed.30851617.s8.e3" /><pair ddi="false" e1="DDI-PubMed.30851617.s8.e3" e2="DDI-PubMed.30851617.s8.e4" /><pair ddi="false" e1="DDI-PubMed.30851617.s8.e3" e2="DDI-PubMed.30851617.s8.e5" /><pair ddi="false" e1="DDI-PubMed.30851617.s8.e3" e2="DDI-PubMed.30851617.s8.e6" /><pair ddi="false" e1="DDI-PubMed.30851617.s8.e4" e2="DDI-PubMed.30851617.s8.e4" /><pair ddi="false" e1="DDI-PubMed.30851617.s8.e4" e2="DDI-PubMed.30851617.s8.e5" /><pair ddi="false" e1="DDI-PubMed.30851617.s8.e4" e2="DDI-PubMed.30851617.s8.e6" /><pair ddi="false" e1="DDI-PubMed.30851617.s8.e5" e2="DDI-PubMed.30851617.s8.e5" /><pair ddi="false" e1="DDI-PubMed.30851617.s8.e5" e2="DDI-PubMed.30851617.s8.e6" /></sentence><sentence text=" Overall, this new bioanalytical method for estimation of bedaquiline in rat plasma was found to be helpful to assess the pharmacokinetics of bedaquiline and very much useful for evaluation of preclinical drug-drug interaction before considering costly and perilous clinical exploration"><entity charOffset="58-69" id="DDI-PubMed.30851617.s9.e0" text="bedaquiline" /><entity charOffset="142-153" id="DDI-PubMed.30851617.s9.e1" text="bedaquiline" /><pair ddi="false" e1="DDI-PubMed.30851617.s9.e0" e2="DDI-PubMed.30851617.s9.e0" /><pair ddi="false" e1="DDI-PubMed.30851617.s9.e0" e2="DDI-PubMed.30851617.s9.e1" /></sentence><sentence text="" /></document>